A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study

International Journal of Hematology
Kimihiro MatsumotoKeio BRB Study Group

Abstract

To evaluate the efficacy and safety of a combined regimen of bendamustine (B) and rituximab (R) in Japanese patients with relapsed/refractory (r/r) indolent B-cell non-Hodgkin lymphomas (B-NHLs) and mantle cell lymphoma (MCL). Patients aged 20-79 years with pathologically confirmed B-NHLs or MCL, which were r/r after 1-2 R-containing regimens, were included in this study. The BR regimen consisted of B (90 mg/m(2)) for two consecutive days and R (375 mg/m(2)) on day 1, 2, or 3. The course was repeated every 4 weeks for up to four cycles. Fifty-three patients were enrolled in this study and analyzed. The diagnosis included follicular lymphoma (FL) (77 %), mucosa-associated lymphoid tissue lymphoma (13 %) and others (10 %). Forty-seven (90 %) patients completed four cycles of treatment as per schedule. Best overall response rate (ORR) and complete response rate (CRR) was 94 and 71 %, respectively (for FL, ORR 95 % and CRR 80 %). The treatment was well tolerated and the primary toxicity was myelosuppression; the incidence of grade 3/4 leukopenia and neutropenia were 42 and 40 %, respectively. There were no grade 5 toxicities. The BR regimen is safe in Japanese patients with r/r indolent B-NHLs and MCL, and is effective for those wi...Continue Reading

References

Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y BastionB Coiffier
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Oct 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry C SchoutenGunnar Kvalheim
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mathias J RummelParis S Mitrou
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kensei TobinaiTomomitsu Hotta
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Sue RobinsonBruce D Cheson
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abdulwahab J Al-TourahJoseph M Connors
Jul 16, 2010·Cancer Science·Ken OhmachiUNKNOWN Japanese Bendamustine Lymphoma Study Group
Oct 15, 2010·European Journal of Haematology·Sari RiihijärviSirpa Leppä
Apr 19, 2012·Haematologica·Ulrich JägerUNKNOWN Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators
Jan 9, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·UNKNOWN Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology

❮ Previous
Next ❯

Citations

Jun 14, 2018·The Oncologist·Haige YeMichael L Wang
Mar 3, 2020·Biological & Pharmaceutical Bulletin·Shigeru IshidaNobuaki Egashira
Jun 4, 2019·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hiroyuki WatanabeSatohiro Masuda
Mar 21, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jacob D SoumeraiJohn F Gerecitano
Feb 27, 2021·Deutsches Ärzteblatt International·Anna ZoellnerWolfgang Hiddemann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.